MedTrace Logo

Convalescent Plasma in the Treatment of Covid-19

NCT04730401 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2022-07-07

No results posted yet for this study

Summary

This study investigates the possible adverse effects and effectiveness of convalescent plasma for patients infected with SARS-CoV-2. Following provision of informed consent, patients will be randomized into three groups: High-titre convalescent plasma, low-titre convalescent plasma or placebo. Primary outcomes of the study will cover safety and either intubation or initiation of systemic corticosteroids. Safety information collected will include serious adverse events judged to be related to administration of convalescent plasma. Microbiological and other laboratory parameters will be followed up.

Conditions

  • Covid19

Interventions

BIOLOGICAL

Convalescent plasma from COVID-19 donors

Convalescent plasma from COVID-19 donors

BIOLOGICAL

Placebo

200mL saline

Sponsors & Collaborators

  • Finnish Red Cross Blood Service

    collaborator OTHER

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Anu Kantele, MD,Prof · Helsinki University Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-27
Primary Completion
2022-01-30
Completion
2023-01-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730401 on ClinicalTrials.gov